News | News By Subject | News by Disease News By Date | Search News

Leukemia (T-cell) News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
FDA Accepts Pharmacyclics, Inc. (PCYC)'s New Drug Application for Ibrutinib     8/29/2013
Biocryst Pharmaceuticals (BCRX) Receives Special Protocol Assessment (SPA) From FDA For Pivotal Trial Of Fodosine(TM) In T-Cell Leukemia     8/7/2006
GlaxoSmithKline (GSK) Announces Approval Of ARRANON(R) Injection     10/28/2005
Biocryst Pharmaceuticals (BCRX) Receives FDA Fast Track Status For Fodosine(TM) In The Treatment Of Relapsed Or Refractory T-cell Leukemia     6/20/2005
Ligand Pharmaceuticals Inc. (LGND) Exercises First Option To Buy Down ONTAK Royalties     1/7/2005
Biocryst Pharmaceuticals (BCRX) Receives Orphan Drug Designation For BCX-1777 In Two Additional Cancer Indications     8/24/2004

News from Around the Web

Press Releases
Calithera Biosciences, Inc. (CALA) Reports Phase I Data For CB-839 In Patients With Acute Leukemias At The 20th Congress Of The European Hematology Association     6/12/2015
Bio-Path Holdings, Inc. (BPTH) Granted Orphan Drug Designation For Liposomal Grb-2 In Acute Myeloid Leukemia     4/28/2015
Juno Therapeutics's JCAR015 Leukemia T Cell Therapy Granted Orphan Drug Designation By FDA     11/18/2014
Biocryst Pharmaceuticals (BCRX) Announces Presentation Of Fodosine(TM) Data During The 47th Annual Meeting And Exposition Of The American Society of Hematology     12/12/2005
Expert From The Leukemia & Lymphoma Society Available To Comment On Presentations From Annual American Society of Hematology Conference     12/6/2005
Viragen's (VRA) Multiferon(R) Approved For Sale In Chile     6/20/2005
Biocryst Pharmaceuticals (BCRX) Initiates Phase II Clinical Trial Of BCX-1777 In T-Cell Leukemia     4/1/2004
GlaxoSmithKline's (GSK) Nelarabine Is Active In Aggressive, Treatment-Resistant Forms Of Childhood T-Cell Leukemia     12/10/2003

//-->